Press Release

Replicor publishes the initial pre-clinical development of its NAP technology, including REP 2055, for the treatment of chronic HBV infection.

November 2013 – Two papers detailing the initial pre-clinical development of Replicor’s NAP technology for the treatment of chronic HBV infection were published in the November 2013 (Volume 57) edition of the journal Antimicrobial Agents and Chemotherapy.  These papers cover the initial in vitro and in vivo studies done with NAP compounds in collaboration with the lab of Dr. Allison Jilbert at the University of Adelaide, Adelaide, Australia and describe the optimized NAP REP 2055 (REP 9AC) which was first used to treat human patients.

Links to these articles:
Read more
Read more